| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| José María Sánchez Montero, Angel Agis-Torres, David Solano, Monica Söllhuber, María Fernandez, Wilma Villaro, María Gómez-Cañas, Moisés García-Arencibia, Javier Fernández-Ruiz, Javier Egea, María Isabel Martín, Rocío Giró. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease. European journal of pharmacology. vol 895. 2021-05-19. PMID:33460612. |
given that neuronal degeneration in alzheimer's disease (ad) is caused by the combination of multiple neurotoxic insults, current directions in the research of novel therapies to treat this disease attempts to design multitarget strategies that could be more effective than the simply use of acetylcholinesterase inhibitors; currently, the most used therapy for ad. |
2021-05-19 |
2023-08-13 |
Not clear |
| Yilei Song, Xiangyu Wang, Xingrong Wang, Jianze Wang, Qiulian Hao, Jifu Hao, Xueqin Ho. Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer's Disease via Intranasal Administration. Oxidative medicine and cellular longevity. vol 2021. 2021-05-18. PMID:33564364. |
ost-ne improved the spatial memory ability, increased the acetylcholine content in the cerebral cortex, and decreased the activity of acetylcholinesterase in the hippocampus of alzheimer's disease model mice. |
2021-05-18 |
2023-08-13 |
mouse |
| Aihong Yang, Qiao Yu, Hui Ju, Lulu Song, Xiaodi Kou, Rui She. Design, Synthesis and Biological Evaluation of Xanthone Derivatives for Possible Treatment of Alzheimer's Disease Based on Multi-Target Strategy. Chemistry & biodiversity. vol 17. issue 10. 2021-05-17. PMID:32692899. |
four xanthone derivatives were synthesized and evaluated as acetylcholinesterase inhibitors (acheis) with metal chelating ability and antioxidant ability against alzheimer's disease (ad). |
2021-05-17 |
2023-08-13 |
Not clear |
| Li Luo, Qing Song, Yan Li, Zhongcheng Cao, Xiaoming Qiang, Zhenghuai Tan, Yong Den. Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease. Bioorganic & medicinal chemistry. vol 28. issue 8. 2021-05-14. PMID:32146060. |
design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against alzheimer's disease. |
2021-05-14 |
2023-08-13 |
Not clear |
| Marco Catto, Leonardo Pisani, Eugenio de la Mora, Benny Danilo Belviso, Giuseppe Felice Mangiatordi, Andrea Pinto, Annalisa De Palma, Nunzio Denora, Rocco Caliandro, Jacques-Philippe Colletier, Israel Silman, Orazio Nicolotti, Cosimo Damiano Altomar. Chiral Separation, X-ray Structure, and Biological Evaluation of a Potent and Reversible Dual Binding Site AChE Inhibitor. ACS medicinal chemistry letters. vol 11. issue 5. 2021-05-14. PMID:32435398. |
acetylcholinesterase (ache) inhibitors (acheis) still remain the leading therapeutic options for the symptomatic treatment of cognitive deficits associated with mild-to-moderate alzheimer's disease. |
2021-05-14 |
2023-08-13 |
Not clear |
| Diogo Alexandre Siebert, Juliana Soares Campos, Michele Debiasi Alberton, Luciano Vitali, Gustavo Amadeu Mick. Dual electrophoretically-mediated microanalysis in multiple injection mode for the simultaneous determination of acetylcholinesterase and α-glucosidase activity applied to selected polyphenols. Talanta. vol 224. 2021-05-14. PMID:33379009. |
acetylcholinesterase (ache) and α-glucosidase (α-glu) are key target enzymes in the search for novel strategies in the treatment of alzheimer's disease and type ii diabetes. |
2021-05-14 |
2023-08-13 |
Not clear |
| Amit Kumawat, Shabnam Raheem, Fasil Ali, Tanveer Ali Dar, Suman Chakrabarty, Masood Ahmad Rizv. Organoselenium Compounds as Acetylcholinesterase Inhibitors: Evidence and Mechanism of Mixed Inhibition. The journal of physical chemistry. B. vol 125. issue 6. 2021-05-14. PMID:33538163. |
acetylcholinesterase (ache) inhibitors are actively used for the effective treatment of alzheimer's disease. |
2021-05-14 |
2023-08-13 |
Not clear |
| Xiao Sang, Minhe Yang, Jingqian S. Research on endophytic fungi for producing huperzine A on a large-scale. Critical reviews in microbiology. vol 46. issue 6. 2021-05-13. PMID:32970952. |
huperzine a (hupa) is an effective inhibitor of acetylcholinesterase and has attracted great interest as a therapeutic candidate for alzheimer's disease. |
2021-05-13 |
2023-08-13 |
Not clear |
| Martina Bortolami, Daniele Rocco, Antonella Messore, Roberto Di Santo, Roberta Costi, Valentina Noemi Madia, Luigi Scipione, Fabiana Pandolf. Acetylcholinesterase inhibitors for the treatment of Alzheimer's disease - a patent review (2016-present). Expert opinion on therapeutic patents. vol 31. issue 5. 2021-05-12. PMID:33428491. |
acetylcholinesterase inhibitors for the treatment of alzheimer's disease - a patent review (2016-present). |
2021-05-12 |
2023-08-13 |
Not clear |
| Rumyana Simeonova, Dimitrina Zheleva, Iva Valkova, Georgi Stavrakov, Irena Philipova, Mariyana Atanasova, Irini Doytchinov. A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders. Molecules (Basel, Switzerland). vol 26. issue 7. 2021-05-12. PMID:33806197. |
the acetylcholinesterase (ache) inhibitors are the main drugs for symptomatic treatment of neurodegenerative disorders like alzheimer's disease. |
2021-05-12 |
2023-08-13 |
mouse |
| Cüneyt Türkeş, Suleyman Akocak, Mesut Işık, Nebih Lolak, Parham Taslimi, Mustafa Durgun, İlhami Gülçin, Yakup Budak, Şükrü Beydemi. Novel inhibitors with sulfamethazine backbone: synthesis and biological study of multi-target cholinesterases and α-glucosidase inhibitors. Journal of biomolecular structure & dynamics. 2021-05-05. PMID:33950796. |
inhibition of metabolic enzymes such as cholinesterases (ches; acetylcholinesterase, ache and butyrylcholinesterase, bche) and α-glucosidase (α-gly) is one of the accepted approaches in the treatment of alzheimer's disease (ad) and diabetes mellitus (dm). |
2021-05-05 |
2023-08-13 |
Not clear |
| Yu Zhou, Yan Fu, Wanchao Yin, Jian Li, Wei Wang, Fang Bai, Shengtao Xu, Qi Gong, Tao Peng, Yu Hong, Dong Zhang, Dan Zhang, Qiufeng Liu, Yechun Xu, H Eric Xu, Haiyan Zhang, Hualiang Jiang, Hong Li. Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate. Journal of medicinal chemistry. vol 64. issue 4. 2021-05-04. PMID:33570950. |
the acetylcholinesterase (ache) inhibitors remain key therapeutic drugs for the treatment of alzheimer's disease (ad). |
2021-05-04 |
2023-08-13 |
Not clear |
| Eman Shawky, Samah M El Sohafy, Jean Paulo de Andrade, Warley de Souza Borge. Profiling of acetylcholinesterase inhibitory alkaloids from some Natural product research. vol 35. issue 5. 2021-05-03. PMID:30990078. |
profiling of acetylcholinesterase inhibitory alkaloids from some acetylcholinesterase (ache) inhibitors remain the class of drugs used for the treatment of alzheimer disease (ad). |
2021-05-03 |
2023-08-13 |
Not clear |
| Jie Wu, Marco Pistolozzi, Siyu Liu, Wen Ta. Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorganic & medicinal chemistry. vol 28. issue 5. 2021-04-27. PMID:32008882. |
rivastigmine, a dual inhibitor of acetylcholinesterase (ache) and butyrylcholinesterase (bche), has been approved by u.s. food and drug administration to treat alzheimer's disease (ad) and parkinson's disease (pd) dementia. |
2021-04-27 |
2023-08-13 |
Not clear |
| Xi Rong, Liwei Jiang, Meijie Qu, Syed Shams Ul Hassan, Zongchao Li. Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy: A Comprehensive Review. Current pharmaceutical design. vol 27. issue 3. 2021-04-26. PMID:33100197. |
the most worldwide famous acetylcholinesterase inhibitor (acheis) donepezil for its dominant role in alzheimer's disease (ad) has also attracted the attention of many pharmaceuticals due to its promising pharmacological potencies such as neuroprotective, muscle relaxant, and sleep inducer. |
2021-04-26 |
2023-08-13 |
Not clear |
| Hardeep Sandhu, Rajaram Naresh Kumar, Prabha Gar. Machine learning-based modeling to predict inhibitors of acetylcholinesterase. Molecular diversity. 2021-04-23. PMID:33891263. |
acetylcholinesterase enzyme is responsible for the degradation of acetylcholine and is an important drug target for the treatment of alzheimer's disease. |
2021-04-23 |
2023-08-13 |
Not clear |
| François-Xavier Toublet, Julien Lalut, Bérénice Hatat, Cédric Lecoutey, Audrey Davis, Marc Since, Sophie Corvaisier, Thomas Freret, Jana Sopková-de Oliveira Santos, Sylvie Claeysen, Michel Boulouard, Patrick Dallemagne, Christophe Rochai. Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT European journal of medicinal chemistry. vol 210. 2021-04-22. PMID:33310288. |
pleiotropic prodrugs: design of a dual butyrylcholinesterase inhibitor and 5-ht beside acetylcholinesterase, butyrylcholinesterase could be considered as a putative target of interest for the symptomatic treatment of alzheimer's disease (ad). |
2021-04-22 |
2023-08-13 |
Not clear |
| Samaneh Zarei, Mohammad Shafiei, Maryam Firouzi, Loghman Firoozpour, Kouros Divsalar, Ali Asadipour, Tahmineh Akbarzadeh, Alireza Foroumad. Design, synthesis and biological assessment of new 1-benzyl-4-((4-oxoquinazolin-3(4 Heliyon. vol 7. issue 4. 2021-04-21. PMID:33869871. |
emerging of the dual acetylcholinesterase (ache)/butyrylcholinesterase (buche) inhibitors has increased for treating alzheimer disease. |
2021-04-21 |
2023-08-13 |
Not clear |
| HyunChul Youn, Kang Joon Lee, Shin-Gyeom Kim, Seong-Jin Cho, Woo Jung Kim, Won Joon Lee, Jae Yeon Hwang, Changsu Han, Cheolmin Shin, Han-Yong Jun. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial. Psychiatry investigation. vol 18. issue 3. 2021-04-09. PMID:33685036. |
the behavioral effects of combination therapy of memantine and acetylcholinesterase inhibitors compared with acetylcholinesterase inhibitors alone in patients with moderate alzheimer's dementia: a double-blind randomized placebo-controlled trial. |
2021-04-09 |
2023-08-13 |
Not clear |
| HyunChul Youn, Kang Joon Lee, Shin-Gyeom Kim, Seong-Jin Cho, Woo Jung Kim, Won Joon Lee, Jae Yeon Hwang, Changsu Han, Cheolmin Shin, Han-Yong Jun. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial. Psychiatry investigation. vol 18. issue 3. 2021-04-09. PMID:33685036. |
this study aimed to investigate treatment effects of combination therapy of memantine and acetylcholinesterase inhibitors (acheis) compared with acheis alone on behavioral and psychological symptoms of dementia (bpsd) in patients with moderate alzheimer's dementia (ad). |
2021-04-09 |
2023-08-13 |
Not clear |